Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.69 |
| ▸ | PRCP | P42785 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1124672 | 0.98 | PNMT (0.68) | PNMTPRCPHRH3HTR2AHTR2C | |
| Acetic Acid SCHEMBL5456076 | 0.91 | PNMT (0.59) | PNMTPRCPHRH3HTR2AHTR2C | |
| SCHEMBL506134 | 0.87 | HTR2C (0.60) | PNMTHTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL31233660 | 0.86 | PNMT (0.56) | PNMTHTR2CHTR2BCD274DRD2 | |
| SCHEMBL2358135 | 0.86 | PNMT (0.56) | PNMTHTR2CHTR2BCD274DRD2 | |
| Hydrochloric Acid SCHEMBL506120 | 0.86 | HTR2C (0.58) | PNMTHTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL5086121 | 0.85 | PNMT (0.61) | PNMTPRCPCD274 | |
| Hydrochloric Acid SCHEMBL11487923 | 0.84 | PNMT (0.59) | PNMTPRCPCD274 | |
| Hydrochloric Acid SCHEMBL33527957 | 0.84 | PNMT (0.55) | PNMTHTR2CHTR2BCD274DRD2 | |
| Hydrochloric Acid SCHEMBL1124611 | 0.84 | PNMT (0.55) | PNMTHTR2CHTR2BCD274DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| WO-2023207911-A1 | BICYCLIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION | 上海医药集团股份有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116925106-A | Bicyclic heterocyclic compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO PHARMA (FR) | 2023-05-18 | — | — | US | disclosed |
| CN-116082333-A | Pyrimidine piperidine FGFR inhibitor and preparation method and application thereof | 广西鹭港生物医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| EP-4126847-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | ENYO Pharma (FR) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022173849-A1 | (HETERO)ARYLAMINO-CYCLOHEXYL-SULFONYL DERIVATIVES AS CCR6 INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2022-08-18 | — | — | WO | disclosed |
| WO-2021213317-A1 | HPK1 INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 微境生物医药科技(上海)有限公司 (CN) | 2021-10-28 | — | — | WO | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1379493-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076925-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1171434-A1 | TETRAHYDROISOQUINOLINYL-INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-01-16 | — | — | EP | disclosed |
| EP-1131306-A2 | ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6245780-B1 | PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORP | 2001-06-12 | — | — | US | disclosed |
| WO-2000064886-A1 | TETRAHYDROISOQUINOLINYL-INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-02 | — | — | WO | disclosed |
| WO-2000029406-A2 | NOVEL ISOXAZOLINE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150978-A1 | QUINAZOLINONE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | NQO2, NQO1, NDUFV2 | PNMT 2451/4885PRCP 2158/4885HRH3 3038/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | PNMT 559/4885PRCP 2970/4885HRH3 115/4885 |
| US-20230115270-A1 | INHIBITORS OF ADRENORECEPTOR ADRAC2 | ADRA2C, ADRB2, ADRB3 | PNMT 265/4885PRCP 2938/4885HRH3 55/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | PNMT 323/4885PRCP 2232/4885HRH3 216/4885 |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | PNMT 2952/4885PRCP 2677/4885HRH3 1748/4885 |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | PNMT 125/4885PRCP 2953/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.